The article argues that vaccine safety systems need better ways to recognize and study persistent multisystem symptoms reported after immunization.
Evidence
This critique and reform proposal integrates clinical, regulatory, experiential, and patient-perspective evidence to define as a surveillance framework.
Caveat
It does not establish a causal relationship between vaccination and these chronic syndromes and is a conceptual policy analysis rather than an epidemiologic test.
Simplified
The COVID-19 pandemic has renewed attention to complex chronic health conditions that challenge conventional biomedical paradigms. Syndromes such as postural orthostatic tachycardia syndrome and myalgic encephalomyelitis/chronic fatigue syndrome have gained broader visibility through the lens of Long COVID. As global vaccination campaigns expanded, a subset of individuals began reporting similarly persistent, multisystem symptoms following COVID-19 immunization-informally referred to as . These presentations, which include dysautonomia, neuropathic pain, post-exertional malaise, and cognitive dysfunction, resemble post-infectious syndromes and may involve shared immune-related mechanisms. Although no causal relationship to vaccination has been established, these cases-together with comparable reports following other vaccines-highlight limitations in current vaccine safety systems for detecting and evaluating complex chronic outcomes. This article introduces the concept of (CC-AEFIs) as a pragmatic, surveillance-oriented framework to support the systematic identification and investigation of such cases. CC-AEFIs are not syndromic diagnoses but a higher-order category encompassing persistent, multifactorial conditions that may follow immunization yet challenge existing pharmacovigilance definitions and tools. These conditions often involve multiple organ systems, delayed onset, fluctuating trajectories, diagnostic ambiguity, and symptom heterogeneity. Drawing on the author's lived experience as an affected patient and integrating clinical, regulatory, and experiential evidence, the analysis examines structural and epistemic limitations across the pharmacovigilance continuum-from underrecognition in clinical settings to analytic exclusion and constrained governance. It concludes by proposing reforms to strengthen safety-system responsiveness, including enhanced diagnostic training, longitudinal surveillance, patient-reported outcome integration, and analytic transparency. Addressing these limitations is essential to sustain public trust, ensure equitable care, and uphold the scientific integrity of immunization programs.
Key numbers
26.8 per 10,000
Estimated incidence of POTS following mRNA COVID-19 vaccination
Incidence rate of POTS compared to general population levels.
9.2 per 10,000
Excess incidence of POTS compared to pre-vaccination baseline
Rate of POTS cases beyond expected baseline levels.
below 1 per 10,000
Documented rates of following COVID-19 vaccination
Incidence of cases in vaccinated populations.
Full Text
We can’t show the full text here under this license.
The author reported being an affected patient with lived experience of a serious adverse event following immunization and a dual researcher–patient role, while declaring no financial or other non-financial conflicts of interest.
